2023 Meeting Magazine - 36

THE ONLY PEN
4 INJECTIONS A YEAR
FOR PsA AND Ps WITH
AFTER 2 INITIATION DOSES1
Scan this QR code or visit SkyriziHCP.com/rheumatology to learn more about SKYRIZI for PsA
INDICATIONS1
Psoriatic Arthritis: SKYRIZI is indicated for the treatment of active psoriatic arthritis in adults.
Plaque Psoriasis: SKYRIZI is indicated for the treatment of moderate to severe plaque
psoriasis in adults who are candidates for systemic therapy or phototherapy.
IMPORTANT SAFETY INFORMATION1
Hypersensitivity Reactions
SKYRIZI®
(risankizumab-rzaa) is contraindicated in patients with a
history of serious hypersensitivity reaction to risankizumab-rzaa or
any of the excipients. Serious hypersensitivity reactions, including
anaphylaxis, have been reported with the use of SKYRIZI. If a
serious hypersensitivity reaction occurs, discontinue SKYRIZI and
initiate appropriate therapy immediately.
Infection
SKYRIZI may increase the risk of infection. Do not initiate
treatment with SKYRIZI in patients with a clinically important
active infection until it resolves or is adequately treated.
In patients with a chronic infection or a history of recurrent infection,
consider the risks and benefi ts prior to prescribing SKYRIZI. Instruct
patients to seek medical advice if signs or symptoms of clinically
important infection occur. If a patient develops such an infection
or is not responding to standard therapy, closely monitor and
discontinue SKYRIZI until the infection resolves.
Tuberculosis (TB)
Prior to initiating treatment with SKYRIZI, evaluate for TB infection
and consider treatment in patients with latent or active TB for whom
an adequate course of treatment cannot be confi rmed. Monitor
patients for signs and symptoms of active TB during and after SKYRIZI
treatment. Do not administer SKYRIZI to patients with active TB.
Administration of Vaccines
Avoid use of live vaccines in patients treated with SKYRIZI.
Medications that interact with the immune system may increase the
risk of infection following administration of live vaccines. Prior to
initiating SKYRIZI, complete all age appropriate vaccinations according
to current immunization guidelines.
Adverse Reactions
Most common (≥1%) adverse reactions associated with SKYRIZI
include upper respiratory infections, headache, fatigue, injection site
reactions, and tinea infections.
In psoriatic arthritis phase 3 trials, the incidence of hepatic events was
higher with SKYRIZI compared to placebo.
SKYRIZI is available in a 150 mg/mL prefi lled syringe and pen.
References: 1. SKYRIZI [package insert]. North Chicago, IL: AbbVie Inc. 2. Data on fi le,
AbbVie Inc. PatientSource/IQVIA data. 2022. 3. Gordon KB, Blauvelt A, Coates L, et al.
Risankizumab long-term safety in patients with psoriatic disease: integrated analyses of data
from psoriasis and psoriatic arthritis clinical trials. Poster presented at: 31st Congress of the
European Academy of Dermatology and Venereology (EADV 2022); Milan, Italy; September
7-10, 2022. 4. Kristensen LE, Papp K, White D, et al. Effi cacy and safety of risankizumab for
active psoriatic arthritis: 100-week results from the KEEPsAKE 1 and KEEPsAKE 2 trials.
Presented at: 31st Congress of the European Academy of Dermatology and Venereology
(EADV 2022); Milan, Italy; September 7-10, 2022. 5. Kristensen LE, Keiserman M, Papp K, et
al. Effi cacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the
randomised, double-blind, phase 3 KEEPsAKE 1 trial. Ann Rheum Dis. 2022;81(2):225-231.
doi:10.1136/annrheumdis-2021-221019 6. Östör A, Van den Bosch F, Papp K, et al. Effi cacy and
safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised,
double-blind, phase 3 KEEPsAKE 2 trial. Ann Rheum Dis. 2022;81(3):351-358. doi:10.1136/
annrheumdis-2021-221048 7. Data on fi le, AbbVie Inc. February 2023.
Please see the Brief Summary of full Prescribing Information on the page adjacent to this advertisement.
© 2023 AbbVie. All rights reserved. SKYRIZI®
and its design are registered
trademarks of AbbVie Biotechnology Ltd. US-SKZR-230005 March 2023

http://www.SkyriziHCP.com/rheumatology

2023 Meeting Magazine

Table of Contents for the Digital Edition of 2023 Meeting Magazine